Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Wellness Coaches Continues Investment in Clinical Services with Latest Acquisition


Wellness Coaches, a leading national provider of clinical and wellbeing solutions, is pleased to announce the acquisition of Corporate Health Solutions (CHS). For over two decades, CHS has been a premier provider of healthcare solutions to employers. Offerings include biometric testing, health coaching, health assessments, and physician consulting services. Wellness Coaches has acquired all CHS client contracts, personnel, technology, and intellectual property to enhance its health and wellbeing offerings and ensure a seamless transition to existing CHS customers.

The acquisition of CHS reinforces Wellness Coaches’ commitment to expanding its suite of clinical and wellbeing capabilities as the Company seeks to continuously raise the bar for what employers and employees should expect from their healthcare partner. The transaction is part of Wellness Coaches’ strategy to consolidate and transform the highly fragmented multibillion-dollar healthcare industry, which is ripe for innovation and disruption. Wellness Coaches is dedicated to leading the industry forward by unlocking the value of fully integrated and comprehensive clinical, wellbeing, and digital health solutions.

“CHS has an amazing team and a long history of success. They deliver highly complementary services, which makes them a perfect fit for us. In addition, this acquisition strengthens Wellness Coaches as a one-stop-shop partner of choice for employers, health plans, and government entities in search of more accessible, effective, and affordable healthcare solutions,” said Rob Putnam, CEO of Wellness Coaches. “Our success has been built by combining high-quality, clinically rigorous, and personalized healthcare services with highly trained and experienced clinicians and coaches. We then rapidly deploy those solutions through customized onsite, near-site, mobile, or virtual solutions to match the needs of any customer. CHS aligns with this model for success perfectly,” Putnam added.

As a result of this transaction, CHS’s customers will now have access to an even wider range of clinical and wellbeing services from a single provider. Collectively, the transactions Wellness Coaches has completed over the past two years demonstrate its commitment to delivering greater continuity and accessibility of care, and empowering people to take charge of their health.

About Wellness Coaches

Since 2002, Wellness Coaches has been a leading provider of clinical, wellbeing, and safety solutions. Our offerings deliver high-quality healthcare, increased engagement, and produce measurable reductions in health and safety risks and costs for our customers. We offer customizable solutions across the full continuum of care, from prevention and wellbeing to robust clinical services. Our offerings include pre-chronic and chronic disease management, primary care, a full range of immunizations, biometric testing and other diagnostic services, healthcare staffing, and pandemic response. With a national network of more than 25,000 healthcare staff, Wellness Coaches can rapidly deploy its services at scale for private, municipal, state, and federal government customers in all 50 states.

Share article on social media or email:

Talarya Brands Consolidates leading California Cannabis Labels, Raises $6m for Growth


Talarya Brands

“The company has seized this moment to drive a consolidation of distressed assets and create a growing business with strong fundamentals in the largest cannabis market in the world.”

California cannabis brands Cream of the Crop and West Coast Trading merged in January with a manufacturing and distribution enterprise to create Talarya Brands. The consolidation play raised $6 million to drive additional acquisitions in the distressed California cannabis sector, according to the company’s CEO, Dustin Milner.

The Talarya merger was driven by D4C, a private-equity investment firm led by James Kinsella and Robert McNeal, who have created multi-Billion dollar exits for investors through distressed industry roll-ups.

The California cannabis industry is roiling from the boom-bust cycle, explains Talarya Brands Chairwoman and D4C partner, Kelly Coyne. “The company has seized this moment to drive a consolidation of distressed assets and create a growing business with strong fundamentals in the largest cannabis market in the world,” says Coyne.

Cream of the Crop consistently ranks in the top 10 best-selling California brands. Combined retail sales of $28 million in 2022 places Talarya Brands in the top 5% of all cannabis producers, according to Headset data. The company focuses on production, sales and distribution of its own products, from flower and pre-rolls to vapes and high-end smokable concentrates. In the fourth quarter of 2022, Talarya Brands launched California’s first vegan, sugar-free gummy called Wanderers.

As for the company’s next steps, Dustin Milner, CEO, says “The cannabis industry nationwide is poised for a consolidation similar to what we have done in California. Talarya is eyeing additional acquisition and expansion opportunities outside of California.”

ABOUT TALARYA

Talarya Brands produces award-winning labels Cream of the Crop, West Coast Trading and Cosmic, with facilities in Northern and Southern California to serve the world’s largest cannabis marketplace.

Share article on social media or email:

Sagora Senior Living promotes Cindy Filpansick and Christal Hoffman to Vice President positions


Sagora Senior Living has promoted two longtime associates to Vice President roles, Sagora Senior Living President Bryan McCaleb announced last week.

Cindy Filpansick, formerly a Regional Director of Operations, has been promoted to Vice President of Operations. In this position, she will support Regional Directors of Operations, helping them to develop strategies that ensure each community continues to provide a high standard of living and care for each resident.

Cindy has been with Sagora for four years.

“Cindy has worked tirelessly leading her region,” McCaleb said. “She always holds her teams accountable and stays committed to our core values of excellence.”

Christal Hoffman has been promoted to Vice President of Corporate Operations. Previously the Corporate Director of Operations, Christal has been with Sagora since 2015, serving in several different positions. In her new role, she will oversee the Home Office operational divisions including Sales & Marketing, Resident Services, Culinary, Lifestyles and Pathways, Maintenance and Business Services.

“Over the past few years, Christal has shown her true leadership capabilities,” McCaleb said. “We could not have gone through these last 11 months without her diligence, hard work and dedication to our Resident First and Team Focused goals.”

###

ABOUT SAGORA SENIOR LIVING

Sagora Senior Living is among the nation’s top 50 senior housing providers and is guided by a Resident First philosophy. The company operates more than 60 communities in 12 states, with

Cottages, Independent Living, Assisted Living and Memory Care living options. For additional information, please visit Sagora.com.

Share article on social media or email:

Virtual Front Desk Solution Provider WelcomeWare® Announces Major Software Update To Platform


welcomeware-announces-major-software-update

WelcomeWare® is rolling out a major software update for all its customers featuring several improvements to the interface to create a more streamlined front desk experience.

Virtual front desk solution provider WelcomeWare® is pleased to announce a major software update to its platform for health care practices, designed to enhance the visitor experience and improve efficiency for receptionists. The update includes several new features that focus on kiosk customizability, such as displaying the name of the receptionist on the kiosk screen, a dynamic waiting room that provides information while visitors are being connected to a receptionist, and a mute button to ensure that private information is not inadvertently shared by the receptionist through the platform.

The update also includes several improvements to the user interface for a more secure and intuitive visitor experience. These include a more efficient login process for receptionists and access to intake documents and forms outside of live call sessions.

WelcomeWare is gradually rolling out the software update to all its clients, who will receive an email with information about the update and plans for training. “We are excited to release these new features and improvements, which are based directly on our customers’ feedback,” said Jeremy Hurewitz, President of WelcomeWare. “We are committed to continually innovating the front desk and providing the best virtual front desk experience possible.”

About WelcomeWare

WelcomeWare provides an all-in-one hardware and software platform that serves as a “live-streaming receptionist.” This allows receptionists to work from home or a centralized location and remotely complete all their front desk responsibilities, serving multiple locations simultaneously, and gathering metrics and insights on those front desk interactions. WelcomeWare’s platform allows customers to never leave a front desk empty, improves staffing flexibility at a reduced cost, and ensures high-quality customer interactions across all their locations.

For more information, please visit http://www.welcomeware.live or contact Jeremy Hurewitz at jeremy.hurewitz@welcomeware.live or by phone at 410-297-0354 or 203-496-8905.

Share article on social media or email:

Healthcare Industry Expert, Mark Gaines, Joins Viewgol as Vice President of Sales, Central


Viewgol Logo

Using enterprise-grade technology, a robust business intelligence team, and RCM experts, Viewgol empowers healthcare organizations to create RCM Heroes.

His background in the healthcare industry and his expertise in driving business growth make him a key member of our team. His ability to provide valuable assistance to clients will be invaluable as we work to improve the financial performance of healthcare organizations. – Reid Storch, CRO, Viewgol

Viewgol, a healthcare RCM data, advisory, and services company, announced today that Mark Gaines has joined the team as Vice President of Sales, Central. Bringing more than 20 years of experience in the healthcare industry and a background in enterprise software sales, Gaines is a multi-faceted component to company growth. With extensive knowledge in healthcare technology, analytics, population health management, value-based care, strategic partnerships, business development, and sales leadership, Gaines has worked with executives at healthcare systems, hospitals, and physician groups. His strong drive for business growth and new product development will support Viewgol’s continued nationwide expansion.

Gaines is excited to join the Viewgol team and contribute to the company’s mission of creating RCM Heroes by bringing RCM data transparency and accountability to every healthcare organization. Viewgol offers a unique approach to healthcare RCM through its enterprise-grade technology, business intelligence team, payer outcomes team, and RCM experts. The company’s primary products, Analytics, Engage, and Comprehensive, provide a range of RCM solutions to healthcare organizations of all sizes.

“As a part of the Viewgol team, I am eager to work with a group of experts in assisting healthcare organizations in improving their RCM processes and financial wellbeing,” said Gaines. “My experience in the healthcare industry will enable me to provide valuable insights and guidance to our clients as a trusted resource.”

Gaines will identify new opportunities to help Viewgol achieve its vision of caring for patients through caring for the financial health of healthcare organizations.

As a valuable resource to Viewgol clients at the executive and operational levels, Gaines works to provide RCM services guided by data, which impact the healthcare organization’s bottom line. He is excited to help grow a successful company and contribute to the growth and expansion of Viewgol as an RCM service provider.

“We are excited to have Mark Gaines join our team at Viewgol,” said Reid Storch, CRO for Viewgol. “His extensive background in the healthcare industry, along with his expertise in driving business growth, make him a key member of our team. Mark’s leadership skills and ability to provide valuable assistance to our clients will be invaluable as we work to improve the financial performance of healthcare organizations.”

Viewgol will meet each medical practice where they have needs. From practices that simply need best-in-class data, to large health organizations that need full RCM services, Viewgol provides customized solutions for RCM success. To learn more about Viewgol and its products and services, visit the official website at Viewgol.com.

About Viewgol

Viewgol is an RCM data, advisory, and services company specializing in healthcare revenue cycle management. Creating RCM Heroes and leading the industry to make RCM data accessible, understandable, and applicable, Viewgol services many healthcare specialties and organizations of diverse sizes. Viewgol’s primary products, Analytics, Engage, and Comprehensive, provide RCM solutions to resolve RCM problems and act on opportunities. Viewgol’s business intelligence team examines every aspect of an organization’s RCM process to detect issues and offer customized solutions. To learn more, please visit Viewgol.com.

Share article on social media or email:

Catalent Completes Commercial-Scale Plasmid DNA Manufacturing Facility in Gosselies, Belgium


Plasmid DNA is a critical component to many biological therapeutics, and Catalent has made this investment in additional manufacturing capacity in anticipation of supporting the growing number of programs through development towards commercialization.

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the opening of a new commercial-scale plasmid DNA (pDNA) manufacturing facility at its European center of excellence for cell therapies, in Gosselies, Belgium.

The state-of-the-art facility contains over 12,000 square feet (1,100 square meters) of development and manufacturing space across multiple cleanrooms for the dedicated production of CGMP-grade pDNA for clinical and commercial-phase supply. It has been designed to be EMA and FDA compliant to support customers with requirements for high-yielding processes at 50 and 300-liter fermentation scale. This will enable a wide range of batch sizes from milligram to multi gram scale.

At the new facility, Catalent will also produce a new range of ‘off-the-shelf’ plasmids to support cell and gene companies. These include adeno-associated virus (AAV) pHelper, which is available now, and Rep/Cap AAV2 and AAV5 plasmids, which will be available later this quarter. Rep/Cap AAV serotypes 1, 3, 6 and 10 will be available later this year.

This commercial-scale pDNA facility is the latest addition to Catalent’s Gosselies campus, which provides comprehensive services for all stages of cell and gene therapy development, including process and analytical development laboratories, technical transfer services, CGMP cleanrooms for manufacturing, dedicated quality control laboratories, Qualified Person (QP), as well as warehousing and logistics support.

“Catalent enables fully integrated viral vector and mRNA services—from our pDNA expertise in Gosselies, to clinical and commercial production of viral vectors for gene therapy, cell therapy, and mRNA in our network—providing critical supply chain continuity and a single CDMO partner from lead identification to commercial manufacturing,” said Manja Boerman, Ph.D., Catalent’s President, BioModalities (Cell, Gene and Protein Therapies). “Plasmid DNA is a critical component to many biological therapeutics, and Catalent has made this investment in additional manufacturing capacity in anticipation of supporting the growing number of programs through development towards commercialization.”

In December 2022, Catalent opened one of the world’s largest cell therapy commercial manufacturing facilities, also located on the Gosselies campus. The facility houses 60,000 square feet (5,600 square meters) of dedicated cell therapy manufacturing space housing multi-product, segregated suites designed to support autologous and allogeneic cell therapy manufacturing.

About Catalent Cell & Gene Therapy 

Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vaccines, Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, and oncolytic viruses. As an experienced and innovative partner, it has a global network of dedicated, development, clinical, and commercial manufacturing facilities, including an EMA- and FDA-licensed viral vector facility, and fill/finish capabilities located in the U.S. and Europe. With integrated solutions for plasmid DNA, viral vectors, and autologous and allogeneic cell therapies through clinical trial packaging and logistics, Catalent can provide full supply chain control, helping innovators get their advanced therapies to patients, faster.

About Catalent

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.

Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.

Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

Photon-Counting CT Enables Lower Contrast Media for Aortic Imaging


We showed that the improved image quality of CTA with photon-counting detector CT systems can be used to reduce the amount of administered contrast media to the patients, without reducing the diagnostic yield of the examination.

Photon-counting detector CT reduces the amount of contrast needed for CT angiography (CTA) while maintaining image quality, according to a new study published today, January 26, in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).

The portion of the aorta that passes through the chest and abdomen is prone to aneurysms. Risk increases with age. Doctors use CTA with contrast media to examine this region of the artery. While the iodinated contrast media used in these exams is considered very safe, there is a higher risk of adverse reactions in patients with kidney disease, or nephropathy.

“Many patients undergoing CTA of the aorta are elderly, and some may suffer from a certain degree of nephropathy,” said senior author Hatem Alkadhi, M.D., M.P.H., from the Department of Diagnostic and Interventional Radiology at University Hospital Zurich in Zurich, Switzerland. “Thus, they might be at risk for a further reduction of their kidney function due to contrast media administration.”

Using less contrast media is also good for the environment, as iodine breakdown products have harmful environmental effects. In addition, the supply of contrast media has suffered from shortages due to COVID-19-related disruptions in the pharmaceutical supply chain.

Photon-counting detector CT is a new technology that can acquire high-quality images at lower contrast media volume than conventional CT scanners that rely on energy-integrating detectors. It also offers diagnostic quality images at lower radiation dose than those of conventional CT.

Dr. Alkadhi and his University Hospital colleague Kai Higashigaito, M.D., led a study that looked at a low-volume contrast media protocol with photon-counting detector CT for CTA of the aorta in the chest and abdomen.

The study included 100 people, mean age 75. Patients underwent CTA with photon-counting detector CT of the aorta in the chest and abdomen. The patients had received a previous CTA with conventional CT at equal radiation doses.

Photon-counting CT had a higher contrast-to-noise ratio, a key measure of image quality, which translates to a low-volume contrast media protocol. Contrast media volume was reduced by 25%.

Two independent readers rated the image quality of photon-counting CT as higher than that of conventional CT at an equal radiation dose.

“We showed that the improved image quality of CTA with photon-counting detector CT systems can be used to reduce the amount of administered contrast media to the patients, without reducing the diagnostic yield of the examination,” Dr. Alkadhi said. “Image quality remained at the same level as that of previous CT angiography examinations in the same patients using a conventional CT, despite the fact that we reduced the contrast media volume.”

Based on the positive results of the study, Dr. Alkadhi and his colleagues have changed their clinical routine. They now adjust the contrast media protocols in patients undergoing CTA of the aorta in the chest and abdomen.

Besides its superior image quality and spatial resolution, photon-counting CT can provide detailed studies of tissue through its spectral imaging capability. Researchers are looking at this as a way to improve studies of the coronary arteries and the heart muscle.

“Based on the initial experience with this new exciting technology, I envision that this detector type will become the standard in CT scanners in the near future,” Dr. Alkadhi said.

###

“CT Angiography of the Aorta Using Photon-counting Detector CT with Reduced Contrast Media Volume.” Collaborating with Drs. Alkadhi and Higashigaito were Victor Mergen, M.D., Matthias Eberhard, M.D., E.B.C.R., Lisa Jungblut, M.D., Monika Hebeisen, M.Sc., Susan Rätzer, Bettina Zanini, Adrian Kobe, M.D., Katharina Martini, M.D., and André Euler, M.D.

Radiology: Cardiothoracic Imaging is edited by Suhny Abbara, M.D., University of Texas Southwestern Medical Center, Dallas, and owned and published by the Radiological Society of North America, Inc. (https://pubs.rsna.org/journal/cardiothoracic)

RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research, and technologic innovation. The Society is based in Oak Brook, Illinois. (RSNA.org)

For patient-friendly information on CT angiography, visit RadiologyInfo.org.

Share article on social media or email: